FloSeal for preventing symptomatic lymphocele after pelvic and/or para-aortic lymphadenectomy in gynecological cancers: a randomized controlled trial

To evaluate the role of FloSeal for preventing symptomatic lymphocele following pelvic and/or para-aortic lymphadenectomy in patients with gynecological cancers. Between October 2014 and April 2015, 40 patients with gynecological cancers planned for surgical management were randomly placed into FloSeal and non-FloSeal groups in a 1:1 ratio. Lymphocele incidence was evaluated using intravenous contrast-enhanced, abdominopelvic computed tomography 3–6 months after surgery. The quality of life questionnaire was completed by patients at 1, 3 and 6 months after surgery. The incidence of symptomatic lymphocele was compared using a chi-square test. All patients underwent bilateral pelvic lymph node dissection, and eight patients in each group (40%vs. 44.4%, p > 0.999) underwent para-aortic lymph node dissection. The mean number of total, right pelvic, left pelvic and para-aortic lymph nodes retrieved was similar between the groups. One patient (1/20, 5%) in the FloSeal group and three (3/18, 16.7%) in the non-FloSeal group developed lymphoceles (p = 0.328). The incidence of symptomatic lymphocele was 0% and 11% (2/18) in the FloSeal and non-FloSeal groups (p = 0.218), respectively. The mean time interval to drain removal (4.8 ± 2.0 days vs. 5.3 ± 2.2 days, p = 0.400) was shorter and the mean drain volume (1656 ± 1362 mL vs. 2022 ± 2301 mL, p = 0.550) was smaller in FloSeal group. The use of FloSeal after pelvic and/or para-aortic lymphadenectomy in patients with gynecological cancers may be effective for preventing symptomatic lymphocele. Clinical Trial registration: NCT01679483.

Lymphocele; Lymphocyst; Lymphadenectomy; Lymph node dissection; Gynecological cancer; FloSeal

[1] Tzanis AA, Antoniou SA, Zacharoulis D, Ntafopoulos K, Tsouvali H, Daponte A. The role of systematic pelvic and para-aortic lymphadenectomy in the management of patients with advanced epithelial ovarian, tubal, and peritoneal cancer: a systematic review and meta-analysis. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2023; 285: 198–203.

[2] Song SY, Park M, Kang BH, Yang JB, Ko YB, Lee M, et al. Distribution of lymphocele following lymphadenectomy in patients with gynecological malignancies. Obstetrics & Gynecology Science. 2020; 63: 700–708.

[3] Volpi L, Sozzi G, Capozzi VA, Ricco’ M, Merisio C, Di Serio M, et al. Long term complications following pelvic and para-aortic lymphadenectomy for endometrial cancer, incidence and potential risk factors: a single institution experience. International Journal of Gynecologic Cancer. 2019; 29: 312–319.

[4] Charoenkwan K, Kietpeerakool C. Retroperitoneal drainage versus no drainage after pelvic lymphadenectomy for the prevention of lymphocyst formation in women with gynaecological malignancies. Cochrane Database of Systematic Reviews. 2017; 6: CD007387.

[5] Ma X, Wang Y, Fan A, Dong M, Zhao X, Zhang X, et al. Risk factors, microbiology and management of infected lymphocyst after lymphadenectomy for gynecologic malignancies. Archives of Gynecology and Obstetrics. 2018; 298: 1195–1203.

[6] Tinelli A, Giorda G, Manca C, Pellegrino M, Prudenzano R, Guido M, et al. Prevention of lymphocele in female pelvic lymphadenectomy by a collagen patch coated with the human coagulation factors: a pilot study. Journal of Surgical Oncology. 2012; 105: 835–840.

[7] Zikan M, Fischerova D, Pinkavova I, Slama J, Weinberger V, Dusek L, et al. A prospective study examining the incidence of asymptomatic and symptomatic lymphoceles following lymphadenectomy in patients with gynecological cancer. Gynecologic Oncology. 2015; 137: 291–298.

[8] Aznar AL, Lloret PE, Moreno CS, Luna-Guibourg R, Negre RR. Laparoscopic approach for symptomatic pelvic and para-aortic lymphoceles. Journal of the Turkish-German Gynecological Association. 2022; 23: 60–62.

[9] Ayhan A, Basaran A, Güler TO. Effects of oxidized regenerated methylcellulose on lymphocyst formation and peritoneum in gynecologic cancer patients. International Journal of Gynecological Cancer. 2010; 20: 23–27.

[10] Sahbaz A, Gungorduk K, Gulseren V, Ozdemir IA, Harma M, Harma M, et al. What are the risk factors for lymphocyst formation apart from lymphnode dissection and lymphnode count in gynecologic malignancy? Geburtshilfe Frauenheilkd. 2016; 76: 403–407.

[11] Prodromidou A, Iavazzo C, Fotiou A, Psomiadou V, Drakou M, Vorgias G, et al. The application of fibrin sealant for the prevention of lymphocele after lymphadenectomy in patients with gynecological malignancies: a systematic review and meta-analysis of randomized controlled trials. Gynecologic Oncology. 2019; 153: 201–208.

[12] Wagner J, McLaughlin T, Pinto K, Tortora J, Gangakhedkar A, Staff I. The effect of a peritoneal iliac flap on lymphocele formation after robotic radical prostatectomy: results from the PLUS trial. Urology. 2023; 173: 104–110.

[13] Waldert M, Remzi M, Klatte T, Klingler HC. Floseal reduces the incidence of lymphoceles after lymphadenectomies in laparoscopic and robot-assisted extraperitoneal radical prostatectomy. Journal of Endourology. 2011; 25: 969–973.

[14] Park J, Nam J. Role of robotic surgery in cervical malignancy. Best Practice & Research Clinical Obstetrics & Gynaecology. 2017; 45: 60–73.

[15] Kakubari R, Kobayashi E, Kakuda M, Iwamiya T, Takiuchi T, Kodama M, et al. Postoperative lymphocyst formation after pelvic lymphadenectomy for gynecologic cancers: comparison between laparoscopy and laparotomy. International Journal of Clinical Oncology. 2022; 27: 602–608.

[16] Frost JA, Webster KE, Bryant A, Morrison J. Lymphadenectomy for the management of endometrial cancer. Cochrane Database of Systematic Reviews. 2017; 10: CD007585.

[17] Park NY, Seong WJ, Chong GO, Hong DG, Cho YL, Park IS, et al. The effect of nonperitonization and laparoscopic lymphadenectomy for minimizing the incidence of lymphocyst formation after radical hysterectomy for cervical cancer. International Journal of Gynecological Cancer. 2010; 20: 443–448.

[18] Matthey-Gié M, Gié O, Deretti S, Demartines N, Matter M. Prospective randomized study to compare lymphocele and lymphorrhea control following inguinal and axillary therapeutic lymph node dissection with or without the use of an ultrasonic scalpel. Annals of Surgical Oncology. 2016; 23: 1716–1720.

[19] Lamblin G, Chauvy L, Rannou C, Mathevet P, Chabert P, Mellier G, et al. Does ultrasonic advanced energy reduce lymphocele incidence in laparoscopic para-aortic lymphadenectomy? European Journal of Obstetrics & Gynecology and Reproductive Biology. 2015; 185: 53–58.

[20] Scholz HS, Petru E, Benedicic C, Haas J, Tamussino K, Winter R. Fibrin application for preventing lymphocysts after retroperitoneal lymphadenectomy in patients with gynecologic malignancies. Gynecologic Oncology. 2002; 84: 43–46.

[21] Grimm C, Polterauer S, Helmy S, Zikan M, Cibula D, Heitz F, et al. A collagen-fibrin patch (Tachosil®) for the prevention of symptomatic lymphoceles after pelvic lymphadenectomy in women with gynecologic malignancies: a randomized clinical trial. BMC Cancer. 2014; 14: 635.

[22] Köhler C, Kyeyamwa S, Marnitz S, Tsunoda A, Vercelino F, Schneider A, et al. Prevention of lymphoceles using floseal and coseal after laparoscopic lymphadenectomy in patients with gynecologic malignancies. Journal of Minimally Invasive Gynecology. 2015; 22: 451–455.